Better Therapeutics rises as feasibility study for therapy meets goals

Better Therapeutics

08/12/2022 14:01

** Shares of Better Therapeutics  BTTX.O  up ~5% at $1.49
premarket
    ** The digital therapeutics co says study evaluating
feasibility of prescription digital therapeutic (PDT) meets
primary goal 
    ** PDTs are software-based interventions in form of devices
or apps, to prevent, manage, or treat mental or physical
conditions
    ** Helps to reduce liver fat in patients with Nonalcoholic
Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis
(NASH) 
    ** Co says use of PDT shows 16% relative reduction in fat
density estimated through an MRI
    ** Co says no device-related adverse events were reported
    ** Co intends to apply for breakthrough device designation
with the FDA, and seek collaboration for developing a
NAFLD/NASH-specific PDT
    **  Stock down ~69.5% YTD, as of last close
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))